Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-neuraminidase monoclonal antibody and application thereof

A technology of antibodies and amino acids, applied in applications, antibodies, anti-enzyme immunoglobulins, etc.

Active Publication Date: 2021-03-30
SHANGHAI INST OF BIOLOGICAL PROD CO LTD
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still many deficiencies in the current research on anti-influenza virus monoclonal antibodies in this field, and there is still a need to develop new anti-NA monoclonal antibodies with good binding effect and strong specificity in this field.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-neuraminidase monoclonal antibody and application thereof
  • Anti-neuraminidase monoclonal antibody and application thereof
  • Anti-neuraminidase monoclonal antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0128] Antibody preparation

[0129] The sequence of the DNA molecule of the antibody or fragment thereof of the present invention can be obtained by conventional techniques, such as PCR amplification or genomic library screening. In addition, the coding sequences for the light and heavy chains can be fused together to form single-chain antibodies.

[0130] Once the relevant sequences are obtained, recombinant methods can be used to obtain the relevant sequences in large quantities. Usually, it is cloned into a vector, then transformed into a cell, and then the relevant sequence is isolated from the proliferated host cell by conventional methods.

[0131] In addition, related sequences can also be synthesized by artificial synthesis, especially when the fragment length is relatively short. Often, fragments with very long sequences are obtained by synthesizing multiple small fragments and then ligating them.

[0132] At present, the DNA sequence encoding the antibody of the ...

Embodiment 1

[0154] Example 1 Monoclonal Antibody Screening

[0155] 4-week-old SPF grade female BALB / c mice were selected, and each mouse was injected with 50ul of NA plasmid containing 50ug, or 50ul of PBS (control group), and then received electric shocks on both sides of the intramuscular injection needle hole. Immunize once every 2 weeks with the same dose and volume of plasmid solution, and immunize 3 times in total. Seven days after the 3 times of immunization, the blood was collected by docking the tail, and the anti-NA antibody titer in the serum was detected. Mice with higher antibody titers were directly immunized with 50ug of NA plasmid in the tail vein, and 3 days later, the spleen cells of the mice were collected for cell fusion. After the fusion of splenocytes and myeloma cells SP2 / 0, aliquot into 96-well cell culture plates, 37°C, 5% CO 2 Cultured in an incubator. Observe the cell state under an inverted microscope, and aspirate the supernatant for antibody detection aft...

Embodiment 2

[0157] Preparation and purification of embodiment 2 monoclonal antibody

[0158] 8-week-old BALB / C female mice, each mouse was inoculated intraperitoneally with PBS or the hybridoma cells prepared in Example 1, and each mouse was injected with 1×10 7 / 0.5ml. After an interval of 5 days, ascitic fluid was collected. Ascites was purified by protein G affinity column, and the collected eluate was put into a dialysis bag and dialyzed against PBS solution.

[0159] The dialyzed eluate was assayed for its concentration, aliquoted, and frozen at -70°C. The purity of the purified antibody was identified by SDS-PAGE gel.

[0160] 12% of SDS-PAGE identification results such as figure 1 As shown, the purity of the antibody can reach more than 95%, and the heavy chain and light chain of the antibody can be seen at about 57kD and 24kD, and its molecular weight is consistent with the theoretical value.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an anti-neuraminidase monoclonal antibody and application of the anti-neuraminidase monoclonal antibody. Specifically, the invention provides a monoclonal antibody D3 of an anti-avian influenza N9 subtype neuraminidase antigen. The antibody provided by the invention has high affinity and strong neuraminidase activity inhibition capability, can inhibit virus plaque formation,can effectively prevent and protect mice from being attacked by H7N9 virus with an infection lethal dose, and can identify highly conservative sites on neuraminidase, and the monoclonal antibody D3 has wide application prospects in prevention, treatment, detection and vaccine design of avian influenza H7N9 in the future.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a monoclonal antibody against avian influenza N9 subtype neuraminidase (Neuraminidase, NA) antigen. In addition, the present invention also relates to the application of the antibody in prevention, treatment and detection. Background technique [0002] On March 29, 2013, the Chinese Center for Disease Control and Prevention confirmed the first case of human infection with avian influenza H7N9 virus. So far, H7N9 has been endemic in China for six consecutive years, with a mortality rate close to 30%, characterized by severe lung disease and acute respiratory distress syndrome (ARD). [0003] The findings suggest that H7N9 viruses have highly efficient replication in mammalian and human airway cells. Because most human infections are associated with direct contact with live poultry, local governments in China have implemented control measures to reduce the prevalence of H7N9 virus in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C07K16/40C12N15/13A61K47/68A61K39/42A61P31/16A61P11/00G01N33/569G01N33/573
CPCC07K16/1018C07K16/40A61K47/6889A61K47/6801A61P31/16A61P11/00G01N33/56983G01N33/573C07K2317/35C07K2317/76C07K2317/34A61K2039/505A61K2039/552
Inventor 熊斐斐陈则刘雪颖罗剑高飞霞
Owner SHANGHAI INST OF BIOLOGICAL PROD CO LTD